Uroplasty, a developer, manufacturer and marketer of medical device products for the treatment of voiding dysfunctions, has received US Patent No. 7,668,598 covering the stimulation method used in the Urgent PC Neuromodulation System.
The Urgent PC Neuromodulation System is a nonsurgical system for treatment of urinary urgency, urinary frequency and urinary urge incontinence, symptoms often associated with overactive bladder.
The Urgent PC Neuromodulation System is a minimally invasive nerve stimulation device designed for office-based treatment of urinary urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder.
Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms. Uroplasty sells the Urgent PC system in the US, Canada, and countries recognizing the CE mark. Outside of the US, Urgent PC is also indicated for the treatment of fecal incontinence.
David Kaysen, president and CEO, said: “The newly-issued patent covers the delivery of current to the sacral nerve through percutaneous electrical stimulation of the tibial nerve with our unique, disposable lead set.
“The newly-issued patent enhances our strong patent protection for Urgent PC, which two recently published studies have shown to be effective for the treatment of patients with urinary symptoms often associated with overactive bladder. We are pleased to have this additional protection on the unique, single-use feature of the stimulation method used in our Urgent PC System.”